Heghine Khachatryan: Heavy Menstrual Bleeding is Not ‘Normal’ – It is Often Missed Pathology
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared a post on LinkedIn:
“Heavy menstrual bleeding is not ‘normal’ — it is often missed pathology.
For too long, heavy menstrual bleeding (HMB) has been normalized, underestimated, and frequently misdiagnosed.
Behind what is often dismissed as a ‘gynecological issue,’ there may be an underlying hemostatic disorder — including von Willebrand disease, platelet function defects, or other coagulation abnormalities.
The clinical reality is concerning:
Many women remain undiagnosed for years, presenting later with anemia, perioperative bleeding, or complications during pregnancy and childbirth.
Pregnancy introduces an additional layer of complexity.
Hemostasis is dynamically altered, and in women with unrecognized bleeding disorders, this may result in:
- increased risk of miscarriage
- postpartum hemorrhage
- preventable maternal morbidity
Misdiagnosis is not benign — it is systemic failure.
We must shift from symptom-based reassurance to structured hemostatic evaluation, especially in:
- adolescents with HMB
- women with iron deficiency
- patients with bleeding history prior to surgical or reproductive interventions
This is not only a clinical issue — it is a matter of health equity, awareness, and diagnostic capacity.
The time has come to integrate hemostasis into routine women’s health assessment — not as an exception, but as a standard.”

Other posts featuring Heghine Khachatryan on Hemostasis Today.
-
Aug 11, 2026, 16:44The Evolving Treatment Landscape of Hemophilia: From Factor Replacement to Gene Therapy
-
Aug 11, 2026, 16:34Advancing Hemophilia Care Through Training and Local Capacity Building – WFH
-
Aug 11, 2026, 16:26Sabrina H.: The Spectrum of PF4-Mediated Thrombotic Disorders
-
Aug 11, 2026, 16:17Mandy Lauw: From CRTH Training to Clinical Trials
-
Aug 11, 2026, 16:05Obi Light Ogbonnia: From 52 Years of Living With Sickle Cell to a Global Stage
-
Aug 11, 2026, 15:42Iva Pruner: Hemostasis, Thrombosis, and a Little Death Metal
-
Aug 11, 2026, 15:25Bradley Maron։ The AI Revolution in Cardiovascular Drug Development
-
Aug 11, 2026, 15:10Jared Rice: When a Negative DAT Doesn’t Mean the Alloimmune Risk Is Gone
-
Aug 11, 2026, 14:58Manuel De Jesus: Validating the Future of Point-of-Care Anemia Monitoring